Key terms
About SNY
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SNY news
May 02
4:59pm ET
Sanofi’s Frexalimab Shows Promise in MS Trial
Apr 30
10:13am ET
FTC expands patent listing challenges for drugs
Apr 29
3:13pm ET
Sanofi price target raised to EUR 98 from EUR 94 at JPMorgan
Apr 26
9:45pm ET
Kepler Capital Keeps Their Hold Rating on Sanofi (SNYNF)
Apr 25
2:35pm ET
DZ BANK AG Keeps Their Hold Rating on Sanofi (SNYNF)
Apr 25
12:01pm ET
Sanofi SA Starts 2024 with Strong Sales Growth
Apr 25
10:35am ET
Jefferies Sticks to Its Buy Rating for Sanofi (SNYNF)
Apr 25
6:47am ET
SNY Earnings: Sanofi Jumps on Healthy Q1 Performance
Apr 25
6:18am ET
Sanofi expects FY24 business EPS to remain relatively stable
Apr 25
6:17am ET
Sanofi reports Q1 IRFS EPS EUR 0.91, down 43.1%
Apr 23
5:32am ET
Buy Rating Affirmed for Sanofi Amid Strong Growth Prospects and Undervalued Stock
Apr 22
11:36am ET
Previously announced Zantac settlement worth $100M, Bloomber says
Apr 22
10:33am ET
Sanofi to pay $100M to settle Zantac cancer lawsuits, Bloomberg says
Apr 22
3:35am ET
UBS Keeps Their Buy Rating on Sanofi (SNYNF)
Apr 19
6:21pm ET
VGK vs. EZU: Which Is the Better European Stock ETF?
Apr 18
2:08pm ET
IGM Biosciences weakness creates ‘interesting opportunity,’ says Stifel
Apr 18
12:26am ET
Maintaining Buy Rating on Sanofi: A Resilient Financial Outlook Despite Currency Headwinds
Apr 17
8:37am ET
IGM Biosciences announces refocusing of Sanofi collaboration
Apr 11
4:46pm ET
Meet First Wave BioPharma: Exclusive interview with CEO James Sapirstein
Apr 05
5:53am ET
Sanofi announces launch of Verorab in UK
Apr 04
9:35am ET
Barclays Sticks to Its Buy Rating for Sanofi (SNYNF)
Apr 03
4:57pm ET
Sanofi to resolve roughly 5,000 Zantac lawsuits in U.S., Bloomberg says
Mar 27
6:36am ET
Dr. Reddy’s enters partnership with Sanofi to distribute vaccines in India
Mar 27
6:25am ET
AstraZeneca, Sanofi announce Beyfortus approved in Japan
Mar 27
6:16am ET
Annexon price target raised to $12 from $11 at Wells Fargo
Mar 20
2:57pm ET
Sanofi’s Amlitelimab Shows Lasting Benefits
Mar 19
1:36am ET
Sanofi’s Buy Rating Affirmed by Analyst on Strong Clinical Trials and Market Opportunities
Mar 13
11:00am ET
European Stocks: Unnoticed Records, Overlooked Opportunities
Mar 11
6:29am ET
Sanofi reports ‘positive’ results from Part 2 of STREAM-AD study
Mar 04
8:48am ET
Sanofi price target lowered to EUR 114 from EUR 120 at Guggenheim
Feb 28
7:39pm ET
Inhibrx downgraded to Hold from Buy at Jefferies
No recent press releases are available for SNY
SNY Financials
Key terms
Ad Feedback
SNY Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SNY Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range